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Abstract
Anaplastic large cell lymphomas (ALCL) are mainly character-
ized by the reciprocal translocation t(2;5)(p23;q35) that
involves the anaplastic lymphoma kinase (ALK) gene and
generates the fusion protein NPM-ALK with intrinsic tyrosine
kinase activity. NPM-ALK triggers several signaling cascades,
leading to increased cell growth, resistance to apoptosis, and
changes in morphology and migration of transformed cells. To
search for new NPM-ALK interactingmolecules, we developed a
mass spectrometry–based proteomic approach in HEK293 cells
expressing an inducible NPM-ALK and identified the tyrosine
phosphatase Shp2 as a candidate substrate. We found that
NPM-ALKwas able to bind Shp2 in coprecipitation experiments
and to induce its phosphorylation in the tyrosine residues Y542
and Y580 both in HEK293 cells and ALCL cell lines. In primary
lymphomas, antibodies against the phosphorylated tyrosine
Y542 of Shp2 mainly stained ALK-positive cells. In ALCL cell
lines, Shp2-constitutive phosphorylation was dependent on
NPM-ALK, as it significantly decreased after short hairpin RNA
(shRNA)–mediated NPM-ALK knock down. In addition, only the
constitutively active NPM-ALK, but not the kinase dead NPM-
ALKK210R, formed a complex with Shp2, Gab2, and growth
factor receptor binding protein 2 (Grb2), where Grb2 bound to
the phosphorylated Shp2 through its SH2 domain. Shp2 knock
down by specific shRNA decreased the phosphorylation of
extracellular signal-regulated kinase 1/2 and of the tyrosine
residue Y416 in the activation loop of Src, resulting in impaired
ALCL cell proliferation and growth disadvantage. Finally,
migration of ALCL cells was reduced by Shp2 shRNA. These
findings show a direct involvement of Shp2 in NPM-ALK
lymphomagenesis, highlighting its critical role in lymphoma
cell proliferation and migration. [Cancer Res 2007;67(9):4278–86]
Introduction
Anaplastic large cell lymphomas (ALCL) represent a subgroup
of non–Hodgkin’s lymphomas characterized by the frequent
chromosomal translocation t(2;5)(p23;q35). As a consequence, the
anaplastic lymphoma kinase (ALK) gene fuses to nucleophosmin
(NPM) gene, resulting in the aberrant expression of the chimeric
protein NPM-ALK (1). The NPM-ALK fusion protein is composed of
the entire catalytic domain of ALK fused to the NPM oligodime-
rization motif that leads to the dimerization of the protein and to
its constitutive autophosphorylation (2). NPM-ALK plays a key role
in ALCL lymphomagenesis and it has been shown to cause
lymphocyte and fibroblast transformation in vitro and in vivo , to
induce cellular proliferation, to inhibit apoptosis, to modify the
cytoskeleton, and to deregulate cell-cell adhesion and migration
(3–6). NPM-ALK kinase is essential for the survival and growth of
ALK-positive ALCLs in vitro and in vivo (7, 8) and exerts its
transforming capacity through phosphorylation and activation of
several cellular pathways such as Ras/extracellular signal-regulated
kinase (Erk), PLC-g, phosphatidylinositol 3-kinase (PI3K)/Akt and
the Jak3/signal transducers and activators of transcription 3 (Stat3;
refs. 9–13). Activation of Ras/Erk pathway through the recruitment
of different adaptor proteins such as SHC and IRS1 leads to
increased ALK-positive ALCL cell growth (14), whereas phosphor-
ylation of Stat3 and stimulation of PI3K pathway prevent cell death
and result in increased cell survival (10, 11). As the molecular
mechanisms mediating the oncogenic properties of NPM-ALK
remain in part unclear, the identification of new interacting
molecules and substrates could further elucidate NPM-ALK–
mediated transformation and, eventually, reveal new potential
targets for drug therapy in lymphomas. Mass spectrometry (MS)–
based proteomics is a powerful tool to study protein-protein
interactions and, in general, to identify molecules involved in
intracellular signaling (15–17). We used a proteomic approach
based on immunoaffinity purification followed by nanoflow
reverse-phase liquid chromatography-tandem MS (LC-MS/MS) to
identify NPM-ALK interacting molecules and substrates. The same
approach has allowed the identification of p130Cas as a new NPM-
ALK downstream molecule required for NPM-ALK cytoskeleton
reorganization and transformation (6). In this study, we report the
identification of the SH2 domain–containing tyrosine phosphatase
Shp2 and elucidate its role in NPM-ALK–mediated transformation.
We show that Shp2 undergoes phosphorylation after association
with NPM-ALK in human ALCL cells and that its activation is
dependent on ALK tyrosine kinase activity. More importantly, our
findings identify Shp2 as a mediator of NPM-ALK oncogenic
properties by promoting ALCL cell proliferation and migration.
Materials and Methods
Cell lines, cell cultures, and reagents. For the in vitro experiments, the
following cell lines were used: Karpas 299, SU-DHL-1, and TS (a subclone of
SUP-M2; NPM-ALK–positive human lymphoid cells), K562 (chronic myeloid
leukemia cell line), CEM, and Jurkat (T lymphoblastic cell lines), all obtained
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from New York University and maintained in RPMI 1640 (BioWhittaker)
containing 10% FCS (7).
Human embryonal kidney (HEK) cells 293T and 293T-Rex Tet-On
(Invitrogen) were cultured in DMEM supplemented with 10% FCS. In 293
Tet systems, the working concentration of tetracycline in the medium was
1 Ag/mL.
Inducible ALK short hairpin (shRNA) SU-DHL-1 and TS (SU-DHL-1 TTA
A5 and TS TTA A5, respectively) cells were obtained by cotransduction with
pLV-tTRKRAB (TTA) vector (18) and pLVTHM vector containing the H1
promoter ALK-shRNA (A5) cassette (7). These cells undergo NPM-ALK
silencing when 1 Ag/mL doxycycline is added to the medium for at least 72 h.
Immunoprecipitation, trypsin digestion, and MS analysis. Anti–
phosphotyrosine immunoprecipitation before MS analysis and protein
identification was done as previously described (6). Briefly, HEK 293T-Rex
Tet-On cells transfected with NPM-ALK or a kinase dead mutant control
NPM-ALKK210R were grown to confluency and induced with 1 Ag/mL
tetracycline for 24 h. Cells were lysed in 20 mmol/LTris (pH 7.4), 150 mmol/L
NaCl, 5 mmol/L EDTA, 0.1% Triton X-100 in the presence of protease and
phosphatase inhibitors. Ten milligrams of cleared cell lysate were
immunoprecipitated with 50 Ag of agarose-conjugated monoclonal 4G10
(Upstate Biotechnology) and 10 Ag monoclonal PY20 (Transduction
Laboratories) and incubated rotating at 4jC overnight. Immunoprecipitated
samples were resolved on SDS-PAGE and silver stained. Bands of interest
were excised from the gel and subjected to in-gel reduction, alkylation, and
digestion with trypsin (Promega). Samples were analyzed by LC-MS/MS
using a nanoflow high performance liquid chromatography system
(Ultimate; LC Packings) interfaced to electrospray quadrupole time-of-flight
(Q-TOF) tandem mass spectrometers (QTOF Ultima or QTOF Micro,
Waters/Micromass). Protein identification was achieved by analyzing MS/
MS spectra using the Mascot software for searching the National Center for
Biotechnology Information nonredundant protein database.
Cell lysis, coimmunoprecipitation, and Western blot analysis.
Total cellular proteins were extracted with 20 mmol/L Tris-HCl (pH 7.4),
150 mmol/L NaCl, 5 mmol/L EDTA, 1% Triton X-100, 1 mmol/L
phenylmethylsulfonyl fluoride, 10 mmol/L NaF, 1 mmol/L Na3VO4, and
protease inhibitors (Roche). Samples were resuspended in the lysis solution
and incubated at 4jC for 30 min. Cell lysates were clarified by
centrifugation at 10,000  g (13,000 rpm) for 10 min at 4jC and the
supernatants were collected and assayed for protein concentration using
the Bio-Rad protein assay method. Thirty micrograms of proteins were run
on SDS-PAGE under reducing conditions.
For immunoprecipitation experiments, 0.5 to 2 mg whole-cell lysates
were precleared with 30 AL protein A–Sepharose beads (Amersham) for
1 h at 4jC, then incubated with 1 to 5 Ag of monoclonal antibody or 5 to
10 Ag of polyclonal antibody at 4jC for 1 h or overnight. Immune complexes
were collected on 40 AL protein A–Sepharose beads, and the beads were
washed thrice with lysis buffer. Bound proteins were recovered by boiling in
Laemmli sample buffer and resolved on SDS-PAGE.
For immunoblotting, proteins were transferred to nitrocellulose,
incubated with the specific antibody, and detected with peroxidase-
conjugated secondary antibodies and enhanced chemiluminescent reagent
(Amersham).
The following antibodies were used: anti-ALK (1:2,000; Zymed),
monoclonal anti-ALK (1:4,000; Zymed), anti–phospho-Tyr (PY20; 1:1,000;
Transduction Laboratories), agarose-conjugated 4G10 (Upstate Biotechnol-
ogy), polyclonal anti–growth factor receptor binding protein 2 (Grb2;
1:2,000; Santa Cruz Biotechnology), anti–phospho-ALK Y1604 (1:1,000; Cell
Signaling Technology), anti-Shp2 (1:1,000; Cell Signaling Technology), anti–
phospho-Shp2 Y542 (1:1,000; Cell Signaling Technology), anti–phospho-Shp2
Y580 (1:1,000; Cell Signaling Technology), anti-Gab2 (1:2,000; Upstate
Biotechnology), anti–phospho-Gab2 (1:1,000; Cell Signaling Technology),
anti-Stat3 (1:1,000; Cell Signaling Technology), anti–phospho-Stat3 (1:1,000;
Cell Signaling Technology), anti–phospho-eIF2a (1:1,000; Cell Signaling
Technology), anti–phospho-Erk1/2 (1:500; Cell Signaling Technology), anti-
Erk1/2 (1:1,000; Santa Cruz Biotechnology), anti–phospho-Src Y416 (1:1,000;
Cell Signaling Technology), anti-Src (1:1,000; Santa Cruz Biotechnology), and
anti-tubulin (1:10,000; Santa Cruz Biotechnology).
Immunohistochemical and immunofluorescence stainings. Three
primary cases of ALK-positive ALCLs were retrieved from the archives of
the Department of Pathology of the University of Torino. Immunohisto-
chemical stainings were done on formalin-fixed, paraffin-embedded or
frozen tissues of ALCLs. All diagnosis were confirmed by CD30 and ALK
stainings. Sections were incubated with primary antibodies anti-ALK
(1:1,000; Zymed), anti-CD30 (clone BerH2, 1:100, DAKO), and against the
phosphotyrosine Y542 of Shp2 (1:100, Cell Signaling Technology). Bound
complexes were revealed by the DAKO’s Envision+ system on a semi-
automated immunostainer. For immunofluorescence stainings, 293T cells
were grown for 12 h on glass coverslips and transiently transfected with
GFP-NPM-ALK or the kinase dead mutant GFP-NPM-ALKK210R for 24 h.
Samples were fixed in PBS containing 4% paraformaldehyde at room
temperature for 10 min and permeabilized with PBS containing 0.3% Triton
X-100 for 5 min. Coverslips were incubated with PBS containing 3% bovine
serum albumin for 1 h at room temperature and stained with primary
antibody for 1 h followed by tetramethyl rhodamine isothiocyanate–
conjugated secondary antibody (1:400; Sigma) for 1 h at room temperature.
Primary antibodies anti-ALK (Zymed), anti–phospho-ALK Y1604 (Cell
Signaling Technology), anti-Shp2 (Cell Signaling Technology), and anti–
phospho-Shp2 Y542 (Cell Signaling Technology) were diluted 1:50 before
use. Nuclei were stained 10 min at room temperature with HOECHST
(300 ng/mL; Sigma). Coverslips were mounted on slides and images were
acquired on a Leica DM LA upright microscope equipped with a DC300F
camera and were analyzed with IM 50 software.
shRNA sequences, DNA constructs, and mutagenesis. NPM-ALK or
the kinase dead mutant NPM-ALKK210R were cloned into pcDNA5TO vector
(Invitrogen) at HindIII/XhoI sites and stably transfected into 293T-Rex
Tet-On cells using Effectene reagents (Qiagen) as previously described (6).
To obtain the Shp2 construct, total cDNA from ALCL cell lines was
amplified using specific primers flanking the Shp2 coding region. Primers
were as follows: Shp2 forward 5¶-CGGAGCCTGAGCAAGGA-3¶ and Shp2
reverse 5¶-CTGAAGTTTTGGCAGGTTTTC-3¶. PCR products were cloned
into PCRII vector using the TA-cloning system (Invitrogen) and sequenced.
For transient transfection in HEK 293T cells, Shp2 was digested to obtain a
BamHI/EcoRV fragment and subcloned in the plasmid vector pcDNA3 at
the same cloning sites (Invitrogen). For lentiviral vectors, Shp2 construct
were digested to obtain a BamHI/EcoRV fragment, blunted with Klenow
enzyme (Roche), and cloned into the SalI-SmaI–blunted sites of the
bidirectional lentiviral vector pCCL.sin.cPPT.polyA.CTE.eGFP (described in
ref. 19) and kindly provided by Dr. Luigi Naldini (San Raffaele Scientific
Institute, Milan, Italy).
Grb2wt and the dominant-negative Grb2P49L (mutated in the NH2-
terminal SH3 domain) and Grb2R86K (mutated in the SH2 domain) were
kindly provided by Dr. A. Pellicer (New York University, New York, NY).
Human Shp2-specific shRNA sequences were designed and cloned into
pLVTHM vector containing the H1 promoter kindly provided by Dr. Trono
[School of Life Sciences, National Center for Competence in Research, E´cole
Polytechnique Fe´de´rale de Lausanne (EPFL), Lausanne, Switzerland; ref. 18]
as previously described (7). The sense strand of Shp2-shRNA that we used is
5¶-GGGCCAGAGCAGTCAGTAA-3¶.
Transfection, lentivirus production, and cell infection. shRNA Shp2
lentiviruses were obtained by cotransfection of HEK 293T with pLVTHM
vector and pMD2VSV-G, pCMV8.74 and pRSV.REV plasmid vectors (18) into
human 293T cell line (Invitrogen). Transfections were done using Effectene
reagent (Qiagen). High-titer lentiviral vector stocks were produced in HEK
293T as previously described (7). Briefly, aliquots of virus, supplemented
with 8 Ag/mL polybrene (Sigma), were used to infect 10  104 TS and
SU-DHL-1 cells and after 72 h the percentages of transduced cells were
analyzed for GFP expression by fluorescence-activated cell sorting (FACS).
Inducible Shp2-shRNA interference SU-DHL-1 and TS cells were obtained
by cotransduction with pLVTHM vector containing the H1 promoter Shp2-
shRNA cassette and pLV-tTRKRAB vector, as described above.
For cell sorting, cells were resuspended at a concentration of 10  106/
mL in basic sorting buffer and then sorted for enhanced green fluorescent
protein (EGFP) expression on a MoFlo High-Performance Cell Sorter (DAKO
Cytomation) as described (6).
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Cell cycle analysis and cell apoptosis assay. Cell cycle analysis was
carried out by flow cytometry. Cells were washed in PBS and fixed for 1 h in
70% ethanol at 4jC. After washing, cells were treated with RNase (0.25 mg/mL)
and stained with propidium iodide (50 Ag/mL). The G1-G0 phase fraction was
calculated using the CellQuest program (BD Pharmigen Biosciences; ref. 7).
Apoptosis was measured by flow cytometry after staining with the
mitochondrion-permeable, voltage-sensitive dye tetramethylrhodamine
methyl ester (TMRM; Molecular Probes). Cells were washed once in PBS
and incubated for 15 min at 37jC in HEPES buffer solution [10 mmol/L
HEPES (pH 7.4), 140 mmol/L NaCl, 2.5 mmol/L CaCl] with 200 nmol/L
TMRM. Cells were analyzed by FACScan using the CellQuest program (BD
Pharmigen Biosciences; ref. 7).
Cell proliferation assay. For cell proliferation assay, 5  104 cells/mL
were grown in triplicate in 24-well plates in complete RPMI. The number of
viable cells was determined each day up to 6 days by trypan blue exclusion.
Chemotaxis assay. Cell migration was evaluated using a 24-well, 8-Am
pore size Transwell system plates (Costar). Purified cells were washed once
in RPMI 1640 (BioWhittaker) containing 0.1% FCS and then adjusted to
9  105 cells in 100 AL in the same medium. Cells (9  105) in 100 AL
medium were placed in triplicate on the top of the Transwell. Stromal-
derived factor-1a (SDF-1a; 100 ng/mL; R&D Systems) in 600 AL of the same
RPMI medium was added to the bottom of the Transwell system. After
3-h incubation at 37jC in a 5% CO2 atmosphere, the inserts of the transwell
chambers were removed and the cells that had migrated to the bottom well
were collected and counted on a hemacytometer (6).
Coculture and flow cytometry analysis. For coculture experiments,
ALCL cells and ALCL cells infected with Shp2 shRNA and control shRNA,
respectively, were mixed in a 1:1 ratio and cultured in standard conditions
for 3 weeks. The same experiment was carried out for control cells CEM and
K562 infected with Shp2 shRNA. GFP expression was checked over time by
FACS and normalized against the initial time point (day 0).
Results
Identification of Shp2 by MS. We developed a MS-based
proteomic approach to identify new substrates of NPM-ALK. We
stably transfected NPM-ALK or the kinase dead mutant NPM-
ALKK210R as a control into human 293T-Rex Tet-On cell line. NPM-
ALK expression was induced by the addition of tetracycline to the
medium (Fig. 1A). We did immunoprecipitations with a mixture of
anti-phosphotyrosine antibodies and compared the band patterns
of NPM-ALK and NPM-ALKK210R samples. The bands present only
in the NPM-ALK sample were digested and analyzed by LC-MS/MS.
LC-MS/MS analysis allowed the identification of previously known
NPM-ALK interacting molecules (PLC-g, PI3K, Stat3, and p130Cas)
and new potential substrates (Fig. 1B). The most abundant protein
at 76 kDa corresponded to NPM-ALK as confirmed by MS analysis.
Duplicate MS/MS analysis of the digested bands resulted in the
identification of 46 unique proteins belonging to different
Gene Ontology functional groups (data not shown). Among
phosphatases, we identified four peptides corresponding to the
SH2 domain–containing phosphatase Shp2 with a 6% sequence
Figure 1. Anti–phosphotyrosine
immunoprecipitation and Shp2
identification by MS. A, T-REx-293 Tet-On
were stably transfected with NPM-ALK or
NPM-ALKK210R as control. NPM-ALK
expression was induced by adding 1 Ag/mL
tetracycline to the medium. Total cell
lysates were blotted with anti-ALK and
anti-phosphotyrosine antibodies.
Anti-phosphotyrosine Western blot shows
that NPM-ALK was phosphorylated,
whereas the dead mutant control
NPM-ALKK210R was not. B, T-REx-293
Tet-On cells transfected with NPM-ALK
were grown in the presence or absence of
tetracycline for 24 h. Total cell lysates
were immunoprecipitated with a mixture of
anti-phosphotyrosine antibodies, run on
SDS-PAGE, and silver stained. Arrows,
bands that were excised from the gel
and analyzed by LC-MS/MS. NPM-ALK
and known interacting molecules
identified by LC-MS/MS are indicated.
C, MS/MS spectrum of Shp2 peptide
221-INAAEIESR-229. Shp2 was identified
by the MS/MS sequencing of four peptides.
Percentage coverage of 6% for Shp2
identification is represented by showing
the identified peptides (bold ) in the total
protein sequence.
Cancer Research
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coverage. MS/MS spectrum of the peptide 221-INAAEIESR-229 is
shown in Fig. 1C . As Shp2 has been described to be involved in the
transformation of other hematologic malignancies (20, 21), we decided
to further elucidate its role in NPM-ALK–mediated lymphomagenesis.
Shp2 phosphorylation is dependent on NPM-ALK tyrosine
kinase activity. Because Shp2 is mutated in a subset of patients
with hematologic malignancies (22, 23), we first ruled out the
presence of activating mutations of Shp2 in ALCL cell lines by
cDNA cloning and sequencing (data not shown). Immunoblotting
total cell lysates from 293T cells with anti-Shp2 antibody showed
the presence of two protein species, suggesting posttranscriptional
modified forms (Fig. 2A). Immunoprecipitation assays with anti-
phosphotyrosine antibody confirmed that Shp2 was phosphorylat-
ed only in the presence of NPM-ALK and not in cells expressing the
kinase dead mutant NPM-ALKK210R, indicating that an active
kinase domain is required for a functional activation (Fig. 2A).
Moreover, Shp2 phosphorylation was detectable in ALCL cells
compared with ALK-negative cell lines (Fig. 2B).
To investigate whether Shp2 phosphorylation was dependent
on NPM-ALK tyrosine kinase activity in ALK-positive ALCL
cells, we generated a doxycycline-dependent anti-ALK shRNA
inducible system to abrogate NPM-ALK expression. TS TTA A5
and SU-DHL-1 TTA A5 cells were cultured in the presence of
doxycycline for 72 h to knock down NPM-ALK expression and
anti-phosphotyrosine immunoprecipitations showed a marked
reduction of Shp2 phosphorylation in both cell lines (Fig. 2C).
Accordingly, the phosphorylation of both the C-tail tyrosine
residues (Y542 and Y580) of Shp2 was significantly reduced after
ALK silencing, as detected by immunoblotting with specific
antibodies (Fig. 2D). We concluded that in ALCL cell lines, Shp2
phosphorylation was strictly correlated to NPM-ALK kinase activity.
By immunofluorescence stainings, only 293T cells transfected
with NPM-ALK, but not untransfected or NPM-ALKK210R kinase
dead mutant, showed a strong signal for phosphorylated Shp2
(Y542; Fig. 3A).
To confirm the findings obtained on ALCL cell lines in primary
tissues, we, then, analyzed ALK-positive lymphomas and found that
Shp2 was strongly phosphorylated in anaplastic cells also
expressing ALK and CD30, whereas surrounding reactive lympho-
cytes showed a weak to negative staining (Fig. 3B).
NPM-ALK forms a complex with Shp2, Gab2, and Grb2. To
explore whether Shp2 associates with NPM-ALK, we did NPM-ALK
immunoprecipitations in 293T-Rex cells. As shown in Fig. 4A , Shp2
associated only with active NPM-ALK, as the binding did not occur
in the presence of the kinase dead mutant NPM-ALKK210R.
Significantly, the association between the two molecules was also
confirmed in ALK-positive cell lines (Karpas 299, SU-DHL-1, and
TS; Fig. 4A). ALK-negative Jurkat and CEM cells were used as
controls. The same results were obtained with anti-Shp2 immuno-
precipitations (data not shown).
Previous studies reported that the association of Shp2 to the
scaffolding adapter protein Gab2 is a frequent event in response to
Figure 2. Shp2 phosphorylation is
dependent on NPM-ALK tyrosine kinase
activity. A, Shp2 is phosphorylated in
the presence of NPM-ALK but not
NPM-ALKK210R. T-REx-293 Tet-On cells
were induced with 1 Ag/mL tetracycline
for 24 h. Total cell lysates were
immunoprecipitated (IP ) with a mixture
of monoclonal anti-phosphotyrosine
antibodies and blotted with anti-Shp2
antibody. B, Shp2 phosphorylation
was clearly detectable in ALK-positive
lymphoma cell lines (Karpas 299,
SU-DHL-1, and TS) compared with
controls (CEM and Jurkat). Lymphoid
cell lines were immunoprecipitated as
described in A. C and D, NPM-ALK
silencing by shRNA decreases Shp2
phosphorylation. TS TTA A5 and
SU-DHL-1 TTA A5 were grown in the
presence of 1 Ag/mL doxycycline and
harvested after 72 h. Total cell lysates were
immunoprecipitated with a mixture of
monoclonal anti-phosphotyrosine
antibodies and blotted with an anti-Shp2
and anti-ALK antibodies (C ), and
were immunoblotted with specific
anti–phospho-Shp2 antibodies (Y542 and
Y580; D ).
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growth factor stimulation (20, 21, 24) and that Gab2 precipitated
with NPM-ALK in ALCL cell lines (11). Therefore, we investigated
whether Gab2 is phosphorylated in a complex with NPM-ALK. In
total cell lysates from 293T-Rex cells, Gab2 was phosphorylated only
in the presence of NPM-ALK (Fig. 4B). Anti-Gab2 immunoprecip-
itation in 293T-Rex cells showed that Gab2 precipitated only with the
active NPM-ALK, but not with the kinase dead mutant (Fig. 4C). The
same results were observed in ALCL cell lines (Fig. 4C). Reciprocal
anti-ALK immunoprecipitation in both HEK293 and ALCL cells
confirmed the above-described association (data not shown).
Because Grb2 has been described to interact with NPM-ALK (14)
and to mediate the recruitment of Shp2 through Gab2 in Bcr-Abl–
transformed leukemia cells (20), we hypothesized that Grb2 was
involved in the interaction of Shp2 with NPM-ALK. Transient
cotransfection experiments in 293T cells showed that Grb2 was
able to bind Shp2 only in the presence of active NPM-ALK (Fig. 4D).
In addition, the use of two dominant-negative forms of Grb2,
mutated, respectively, in the NH2-terminal SH3 domain (P49L) and
in the SH2 domain (R86K), showed that the Shp2 binding to Grb2
was mediated by the SH2 domain of Grb2 as Shp2 did not
precipitate in the presence of R86K Grb2-mutant, whereas the
binding of Shp2 to NPM-ALK was not abrogated (Fig. 4D). This
finding suggests that Grb2 is involved as a downstream molecule of
Shp2 rather than a mediator of the binding to NPM-ALK.
Shp2 activation regulates cell growth in ALK-positive
lymphoma cells. To assess the biological role of Shp2 in human
lymphoma cells, we designed a specific Shp2 shRNA to down-
modulate Shp2 expression. TS and SU-DHL-1 cells were transduced
with Shp2 shRNA and control shRNA lentiviral vectors. Shp2 knock
down was confirmed by immunoblotting with anti-Shp2 antibody
and the unchanged expression level of P-eIF2a excluded unspecific
regulation via IFN-mediated responses (Fig. 5A). To compare the
growth rate of ALCL cells and ALCL cells transduced with Shp2
shRNA, a coculture experiment was done. We found that TS and SU-
DHL-1 cells transiently transduced with Shp2 shRNA had a
significant growth disadvantage compared with untransduced
counterparts, whereas no effect was found in TS and SU-DHL-1
infected with a control shRNA or in a control cell line (CEM)
infected with Shp2 shRNA (Fig. 5B). As expected, K562 infected with
Shp2 shRNA displayed a similar slower rate of proliferation (25, 26;
data not shown). To verify that the proliferative disadvantage was
not derived from off-target effects of the Shp2 shRNA, we did a
functional rescue experiment. As Shp2 shRNA targets a sequence in
the 3¶-untranslated region of Shp2, we cotransduced TS cells with
Shp2 shRNA and a Shp2-EGFP-lentiviral construct that does not
contain the shRNA target sequence. In coculture, TS cells
ectopically expressing Shp2 and Shp2 shRNA were almost
completely rescued to a normal growth (data not shown).
Shp2 down-modulation affects lymphoma cell proliferation
but not apoptosis. To further study the involvement of Shp2 on
ALCL cell proliferation, we generated cell lines carrying a
doxycycline-dependent inducible Shp2 shRNA silencing. TS and
SU-DHL-1 were cotransduced with pLV-tTRKRAB (TTA) and
pLVTHM Shp2 shRNA. Cotransduced cells grown in the presence
of doxycycline efficiently down-regulated Shp2 expression as
shown in Fig. 5C . TS and SU-DHL-1 transduced with the pLV-
tTRKRAB vector only were used as control. The abrogation of Shp2
in both cell lines significantly impaired cellular proliferation over
time compared with cells grown without doxycycline (Fig. 5D) or to
the control cell lines (with or without doxycycline; data not shown).
To understand whether the observed low proliferation rate was due
to cell cycle arrest and/or increased apoptosis, we did cell cycle
Figure 3. Shp2 is phosphorylated in NPM-ALK–expressing 293T cells and in primary ALK-positive human lymphomas. A, immunofluorescence stainings of 293T
cells transfected with NPM-ALK (left ) or NPM-ALKK210R (right ) were done by the indicated specific antibodies (red fluorescence ). Green fluorescence, EGFP reporter
protein encoded by the transfection vectors. All images were taken with a 100 oil-immersion objective. B, formalin-fixed, paraffin-embedded sections from a
representative case of NPM-ALK–positive primary ALCL were stained with H&E (top left ) and with antibodies against CD30 (top right) and ALK (lower left) by
immunohistochemistry. A corresponding frozen section from the same case was stained with the phosphospecific antibody that recognizes the Y542 phosphotyrosine
of Shp2 (lower right ). All images were taken with a 40 objective.
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analysis with propidium iodide staining and TMRM apoptosis
assay. Cell cycle analysis revealed that Shp2 knock down led to a
significant increase in the percentage of TS cells in the G1 phase
and a corresponding decrease in the S and G2-M phases, without
changes in the apoptotic fraction as indicated by the sub–G0-G1
populations (Fig. 6A). Furthermore, the absence of apoptosis was
confirmed by TMRM staining (data not shown). We showed that,
in TS cells, Shp2 knock down led to a decrease in Erk1/2
phosphorylation (Fig. 6B). A similar decrease was observed in the
SU-DHL-1 cell line (Supplementary Fig. S1). Concomitantly, we
observed a decrease in the phosphorylation of the tyrosine residue
Y416 in the activation loop of Src, whereas Stat3 and Akt
phosphorylations were not affected (Fig. 6B). Notably, NPM-ALK
total amount and phosphorylation did not change after Shp2
silencing, thus excluding major effects of Shp2 on NPM-ALK
stability, contrary to what has been described for Bcr-Abl (Fig. 6B ;
ref. 27). These findings indicate that the activation of Shp2 in ALCL
cells regulates the Ras/Erk signaling pathway and the activation of
Src, thus influencing ALCL cell proliferation.
Shp2 knock down reduces spontaneous and SDF-1A–
induced migration of ALCL cells. Our group recently described
that NPM-ALK increases ALCL spontaneous and SDF-1a–induced
cell migration (6). As Shp2 is required for integrin-driven cell
spreading and migration (28, 29) and participates in a-chemokine
receptor CXCR-4–mediated cell signaling in T lymphocytes (30), we
investigated its role in ALCL cell migration. We did a chemotaxis
assay in the inducible TS TTA shShp2 shRNA cells. Shp2 knock
down reduced both the spontaneous migration and the SDF-1a–
induced migration of lymphoma cells, suggesting its role in ALCL
cell migration (Fig. 6C).
Discussion
In this study, we used a functional proteomic approach to
identify new NPM-ALK phosphorylated and/or interacting proteins
by immunoaffinity purification and MS by using 293T-Rex cells
ectopically expressing NPM-ALK under an inducible tetracycline
promoter. In addition to known NPM-ALK substrates, our analysis
Figure 4. NPM-ALK coprecipitates
with Shp2, Gab2, and Grb2. A, Shp2
coprecipitates with NPM-ALK in T-REx-293
and in lymphoma cell lines (Karpas 299,
SU-DHL-1, and TS). Total cell lysates from
T-REx-293 (left) and lymphoid cell lines
(right ) were immunoprecipitated with
anti-ALK antibody and blotted with
anti-Shp2. B, Gab2 is phosphorylated
only in the presence of NPM-ALK.
Total cell lysates from T-REx-293
were immunoblotted with a specific
anti–phospho-Gab2 antibody and
anti-Gab2 antibody as control. C, Gab2
coprecipitates with NPM-ALK in
T-REx-293 and in ALK-positive ALCL
cells. Total cell lysates from T-REx-293
(top ) and lymphoid cell lines (bottom )
were immunoprecipitated with anti-Gab2
antibody and blotted with the indicated
antibodies. D, HEK 293T cells were
cotransfected with Shp2wt and the
indicated constructs. As detected by
anti-Grb2 immunoprecipitation and
anti-Shp2 immunoblotting (top left), Grb2
was able to bind Shp2 only in the presence
of NPM-ALK, and the binding was
disrupted in the presence of Grb2R86K.
Shp2 binding to NPM-ALK was not
abrogated in the presence of both Grb2
dominant-negative mutants (right ).
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revealed novel potential targets. Among the identified proteins, we
found the ubiquitously expressed SH2 domain–containing tyrosine
phosphatase Shp2. We showed that Shp2 forms a complex with
NPM-ALK both in 293T-Rex cells and in ALK-positive ALCL cells
TS, SU-DHL-1, and Karpas 299. In ALCL cells, Shp2 phosphoryla-
tion was higher compared with other cell lines, such as K562 and
Jurkat (data not shown), in which it is reported to be overexpressed
and constitutively phosphorylated (25). More importantly, in ALCL
cells, Shp2 phosphorylation is dependent on NPM-ALK tyrosine
kinase activity as it is almost completely abrogated when NPM-ALK
expression is knocked down by shRNA. As it is reported for other
transforming tyrosine kinases, this phosphorylation status is
indicative of an activation state of Shp2 (20).
It has been shown that Shp2 can bind to receptor tyrosine
kinases (RTK) either directly or through adaptor/scaffolding
molecules such as IRS1 and Gab family molecules (31, 32), and
here we report that NPM-ALK precipitates both Gab2 and Shp2.
Therefore, we can suppose that NPM-ALK forms a multimeric
complex with Gab2 and Shp2 as described for Bcr-Abl, although we
cannot exclude that Shp2 binds directly to NPM-ALK. The Gab2-
Shp2 complex with other tyrosine kinases such as Bcr-Abl very
often involves the adaptor protein Grb2 through the binding of its
SH3 domain to Gab2 or its SH2 domain to the phosphotyrosine
Y542 of Shp2 (20, 33–35). Previous studies showed that Grb2
coprecipitates with NPM-ALK (14), and we show that Shp2-Grb2
interaction is dependent on the catalytic activity of NPM-ALK as
there is no association in the presence of the kinase dead mutant
NPM-ALKK210R. Moreover, the association is mediated by the Grb2-
SH2 domain as its dominant-negative SH2 mutant R86K disrupts
the binding. On the contrary, Shp2 association to NPM-ALK is not
abrogated. As previously described in fibroblasts stimulated with
platelet-derived growth factor or fibroblast growth factor (FGF),
tyrosyl-phosphorylated Shp2 functions as an adaptor protein for
Grb2 although it is controversial whether this association promotes
the full Erk activation (33, 35). In fact, Shp2 is commonly required
for the activation of the Ras/Erk signaling pathway in response to
several cytokines and RTKs (31, 32). Our results reveal that Shp2
knocked down by specific shRNA in ALCL cells results in f50%
reduction of Erk phosphorylation compared with ALCL cells still
expressing the phosphatase. Thus, in ALCL cells, our findings
suggest that Shp2 acts upstream of the Ras pathway, possibly by
recruiting a Grb2/Sos complex. Also, Shp2 could regulate the Ras
pathway activation through the Src family protein-tyrosine kinases
as we observed a strong decrease in the phosphorylation of the
Figure 5. Shp2 regulates cell growth of
ALCL cells. A, Shp2 expression is
abrogated by specific shRNA. TS and
SU-DHL-1 cells were transduced with Shp2
shRNA and control shRNA lentiviral
vectors. After 72 h, protein expression
was knocked down as verified by Western
blot. No up-regulation of nonspecific
IFN-mediated responses was observed as
shown by blotting with anti–P-eIF2a.
B, SU-DHL-1 and TS transduced with
Shp2 shRNA and cocultured with the
untransduced counterpart showed a
significant growth disadvantage according
to Student’s t test (P = 0.001 and
P = 0.0036, respectively). TS and
SU-DHL-1 cells infected with a control
shRNA and the T lymphoblastoid control
cell line CEM infected with Shp2 shRNA
did not change over time. Results are
representative of three different
experiments. C, TS TTA Shp2 shRNA
and SU-DHL-1 TTA Shp2 shRNA were
grown in the presence of 1 Ag/mL
doxycycline for at least 72 h to knock down
Shp2 expression as shown in the Western
blot with anti-Shp2 antibody. TS TTA
and SU-DHL-1 TTA transduced with
pLV-tTRKRAB were only used as controls.
D, Shp2 silencing by shRNA affects
lymphoma cell proliferation. TS TTA and
SU-DHL-1 TTA infected with Shp2 shRNA
were induced with 1 Ag/mL doxycycline
(Doxy ) for 96 h and then plated at
5  104/mL in a 24-well plate. Cells were
counted each day for 6 d by trypan blue
exclusion. Points, mean of triplicates;
bars, SE. One representative experiment
from two independent assays.
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activating tyrosine Y416 of Src after Shp2 silencing by specific
shRNA. This is a conceivable parallel pathway given that upon RTK
stimulation Shp2 regulates PAG/Cbp tyrosyl phosphorylation,
thereby controlling Csk recruitment to Src (36), and Src is activated
by NPM-ALK in ALCL cells (37).
Shp2 has been previously described to be involved in the
transformation of some hematologic malignancies, either acting as
an oncogene or as an effector molecule (20, 21, 25, 26). Moreover,
Shp2 is implicated both in growth factor receptor and integrin
signaling usually with a positive regulatory role, thus promoting
mitogenic and proliferative signals (31, 32) and its phosphatase
activity seems to mediate the transforming capacity of constitu-
tively active forms of some tyrosine kinase receptors such as
epidermal growth factor receptor, FGF receptor 3, and RET (38–40).
ALCL cells transduced with Shp2 shRNA showed a significant
growth disadvantage and a lower proliferation rate compared with
control cell lines. These effects are not related to a decrease in the
NPM-ALK stability in ALCL cells, in contrast to what it has been
described for Bcr-Abl–transformed cells in which Shp2 stabilizes
the protein through an interaction with HSP90 (27). The impaired
proliferation coincided with the reduced activation of Src and of
the Ras/Erk pathway. Interestingly, in ALCL cell lines, knocking
down Erk1/2 by specific shRNA leads to a similar impairment of
cell proliferation as the knock down of Shp2 (41). Taken together,
our results show that in ALCL cells Shp2 is a critical mediator of
NPM-ALK–driven cell growth.
Shp2 has been described to transduce promigratory signals from
various type of receptors (31, 42), including a CXCR4-mediated
signaling pathways in T cells (30). In ALCL cells, our group recently
showed that NPM-ALK is able to influence both spontaneous and
SDF-1a/CXCR4–induced migration (6). Here, we found that Shp2
down-modulation by shRNA decreased significantly the migration
Figure 6. Shp2 knock down leads to
ALCL cell accumulation in G1 by
reducing Ras/Erk pathway activation and
decreases lymphoma cell migration.
A, flow cytometry profiles of propidium
iodide–stained TS TTA Shp2 shRNA
not induced or induced with 1 Ag/mL
doxycycline for 96 h. In the absence of
Shp2, ALCL cells showed a significant
cell cycle arrest in G1, but not increased
sub–G0-G1 populations. One of four
independent experiments. B, TS TTA Shp2
shRNA were induced with 1 Ag/mL
doxycycline for 96 h. In Shp2 knocked
down cells, the phosphorylation of Erk1/2
and of the tyrosine residue Y416 of Src
were decreased, whereas Stat3 and Akt
phosphorylations were not affected.
Samples were incubated with the
indicated antibodies. Phospho–Src Y416,
phospho–Stat3 Y705, Akt, and Erk1/2
phosphorylations were measured by
normalizing the absorbance of the
phosphorylated bands to the total amount
of the indicated proteins (right ). These
findings are representative of two
independent experiments. C, TS TTA Shp2
shRNA cells were induced with 1 Ag/mL
doxycycline for 96 h followed by a
Transwell migration assay in the presence
or absence of the chemokine SDF-1a
(100 ng/mL). Columns, mean of triplicates
for each experiment; bars, SE. One
representative experiment from two
independent assays. Right, Western blot
analysis of Shp2 knock down by shRNA in
the same cell line.
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rate of ALK-positive ALCL cells. It is likely that NPM-ALK might
promote ALCL cell migration through Shp2 engagement, although
further studies are required to better elucidate the mechanism.
In conclusion, our work provides another clue in the molecular
mechanisms underlying NPM-ALK transformation. Our findings
show that Shp2 associates to NPM-ALK and forms a multimeric
complex with Gab2 and Grb2, resulting in the activation of multiple
downstream effectors such as the Ras/Erk pathway and show that
Shp2 plays a critical role in ALK-evoked cell proliferation and
migration.
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